Holen Sie sich die Stockscreener-App
130.82
0.40%
-0.53
Handel nachbörslich:
131.97
1.15
+0.88%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$131.35
Offen:
$131.255
24-Stunden-Volumen:
6.71M
Relative Volume:
1.09
Marktkapitalisierung:
$226.88B
Einnahmen:
$41.95B
Nettoeinkommen (Verlust:
$13.40B
KGV:
17.10
EPS:
7.65
Netto-Cashflow:
$6.35B
1W Leistung:
+3.55%
1M Leistung:
-3.72%
6M Leistung:
+16.36%
1J Leistung:
+15.10%
1-Tages-Spanne:
$130.75
$133.46
1-Wochen-Bereich:
$124.50
$133.46
52-Wochen-Spanne:
$99.71
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Vergleichen Sie ABT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
130.82 | 226.88B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
99.36 | 146.96B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
364.50 | 142.81B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
87.63 | 112.37B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.91 | 41.85B | 5.72B | 4.17B | 259.90M | 6.97 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
3 Relatively Safe Stocks to Buy Right Now - Yahoo Finance
Top Research Reports for McDonald's, Abbott & O'Reilly Automotive - Yahoo Finance
Abbott snags early CE mark for Volt PFA device - MedTech Dive
$11.66 Bn Lateral Flow Assays Market Insights 2025-2030 with Abbott Laboratories, F. Hoffmann-La Roche, Siemens Healthineers, Thermo Fisher Scientific, QuidelOrtho, and PerkinElmer DominatingResearchAndMarkets.com - Bluefield Daily Telegraph
Is Abbott Laboratories (ABT) the Best S&P 500 Stock to Buy for Dividend Growth? - Yahoo Finance
Abbott Laboratories' (NYSE:ABT) five-year earnings growth trails the 13% YoY shareholder returns - Yahoo Finance
Why Abbott Laboratories (ABT) Surged On Thursday? - Insider Monkey
Abbott (ABT) Stock Rises on European Approval - GuruFocus.com
Why Abbott Laboratories Stock Leaped by Almost 4% on Thursday - The Motley Fool
Abbott Laboratories stock outperforms competitors on strong trading day - MSN
Abbott’s Volt enters the PFA fray with CE mark - BioWorld Online
Abbott Secures CE Mark for Volt PFA System, Advancing in Competitive PFA Market - MD+DI
Abbott wins CE Mark for Volt PFA system to treat atrial fibrillation, begins EU rollout - Mass Device
Abbott Receives CE Mark for Pulsed Field Ablation System - Diagnostic and Interventional Cardiology
Oppenheimer maintains Abbott Labs target at $134 on CE Mark nod - Investing.com
Abbott accelerates PFA market competition in Europe with early Volt approval - Medical Device Network
Abbott's new AFib device gets early OK from European regulators - Crain's Chicago Business
May 9th Options Now Available For Abbott Laboratories (ABT) - Nasdaq
BTIG maintains Buy on Abbott Labs stock, $140 target - Investing.com India
Abbott gains CE mark approval for Volt PFA system - Cardiovascular Business
Abbott Laboratories Receives CE Mark Certification for Volt Pulsed Field Ablation System - Marketscreener.com
Abbott Laboratories (ABT): Among Dividend Zombies to Invest in - Insider Monkey
Abbott’s Volt Pulsed Field Ablation Nabs EU Approval - MPO-mag
Abbott’s Volt PFA system gains CE Mark for AFib treatment By Investing.com - Investing.com Australia
Abbott Receives CE Mark For Its Volt(TM) Pulsed Field Ablation System To Treat Patients With Abnormal Heart Rhythms - Marketscreener.com
Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms - Yahoo Finance
Abbott India Finance Director Jyoti Saraph to resign - Medical Dialogues
Diamond Hill Capital is Crazy About Abbott Laboratories (NYSE:ABT) - Insider Monkey
Behind the Scenes of Abbott Laboratories's Latest Options Trends - Benzinga
Abbott gets FDA nod to begin IVL trial after rivals buy up competition - MedTech Dive
The Zacks Analyst Blog Boston Scientific, Abbott and Medtronic - Yahoo Finance
Abbott Enters Intravascular Lithotripsy Market with FDA-Approved IDE - MD+DI
Abbott (ABT) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance
Abbott makes IVL move as FDA approves new clinical trial - Cardiovascular Business
Abbott Laboratories (NYSE:ABT) Receives FDA Approval For Coronary IVL System Trial In US - Simply Wall St
Abbott gets green light for clinical trials of new heart treatment system - Crain's Chicago Business
Abbott launches intravascular lithotripsy trial aimed at clearing coronary arteries - Fierce Biotech
Abbott Laboratories Gets FDA Approval to Assess Investigational Device in Heart Disease Clinical Trial - Marketscreener.com
TD Cowen maintains $135 target for Abbott Labs stock, reiterates Buy - Investing.com
Abbott is making an IVL play with FDA IDE nod - Mass Device
FDA approves Abbott’s CAD treatment trial - Investing.com India
Abbott Wins FDA IDE Nod for Coronary IVL Trial - MPO-mag
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Lateral Flow Assays Market Analysis Report 2025-2030: Next-generation LFAs, Advancement in LFA Solutions and Reagents, and Rising Acceptance of POC Testing - GlobeNewswire Inc.
Jim Cramer On Abbott Laboratories (ABT): “Abbott Labs Stock Is Back on My Radar” - Insider Monkey
Jim Cramer On Abbott Laboratories (ABT): "Abbott Labs Stock Is Back on My Radar" - Yahoo Finance
Global Glucose Biosensor Market Positioned for Accelerated - openPR
Returns At Abbott Laboratories (NYSE:ABT) Are On The Way Up - Yahoo Finance
Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock? - MSN
Abbott Settles Suit on HIV-Testing Patent With Novartis, Grifols - Bloomberg Law
What Does the Market Think About Abbott Laboratories?Abbott Laboratories (NYSE:ABT) - Benzinga
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):